Treatment of cancer

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

Retrieved on: 
Monday, March 1, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Cell biology, Cell therapy, Targeted therapy, Treatment of cancer, Translational glycobiology

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021.

Key Points: 
  • CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021.
  • Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 4, 2021, at 1:30 p.m. E.T.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

Oncternal Therapeutics to Participate in March Investor Conferences

Retrieved on: 
Wednesday, February 24, 2021
Health sciences, Life sciences, Biotechnology, Medicinal chemistry, Cancer, Cirmtuzumab, Treatment of cancer, Oncology, Biopharmaceutical, Therapy

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need.

Key Points: 
  • Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need.
  • Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression.
  • In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
  • More information is available at www.oncternal.com .

Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Wednesday, February 24, 2021
Treatment of cancer

LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. WainwrightGlobal Life Sciences Conference being held virtually from March 9-10, 2021.

Key Points: 
  • LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. WainwrightGlobal Life Sciences Conference being held virtually from March 9-10, 2021.
  • An archived replay will be available on the companys website for a period of 90 days after the conference.
  • Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer.
  • Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.

Therapeutic Solutions International Uses StemVacs™ Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells

Retrieved on: 
Monday, February 22, 2021
Branches of biology, Biology, Medicine, Stem cells, Biotechnology, Cancer treatments, Treatment of cancer, Immunotherapy, Radiation therapy, Cancer stem cell, Chemotherapy, Cancer

"What is impressive about the StemVacs approach is that it can generate personalized T cells that selectively seek and destroy cancer stem cells.

Key Points: 
  • "What is impressive about the StemVacs approach is that it can generate personalized T cells that selectively seek and destroy cancer stem cells.
  • It is the cancer stem cells that are the 'roots' of the cancer.
  • They are resistant to chemotherapy and radiotherapy and to my knowledge the only possible way of eliminating cancer stem cells is through immunotherapy."
  • Researchers believe current cancer treatments sometimes fail because they don't destroy the cancer stem cells.

2021 Szent-Györgyi Prize Awarded to Pioneering Research Duo Who Have Paved the Path to Life-Saving T-Cell Receptor-Based Cancer Immunotherapies

Retrieved on: 
Thursday, February 18, 2021
National Foundation for Cancer Research, Szent-Györgyi Prize for Progress in Cancer Research, Treatment of cancer, Cancer, American culture, Awards, Medicine, Harvard Medical School

These combined discoveries marked the beginning of a new era, making prior-to-which elusive cell-based immune-therapy a medical reality and effective new form of cancer treatment.

Key Points: 
  • These combined discoveries marked the beginning of a new era, making prior-to-which elusive cell-based immune-therapy a medical reality and effective new form of cancer treatment.
  • Since then, both Mak and Davis have also made several other important and often complementary contributions in the fields of immunology, cancer biology and cancer therapy.
  • The Szent-Gyrgyi Prize for Progress in Cancer Research was established by the National Foundation for Cancer Research in honor of its co-founder, Albert Szent-Gyrgyi, M.D., Ph.D., recipient of the 1937 Nobel Prize for Physiology and Medicine.
  • Since its establishment in 1973, NFCR has provided more than $390 million for cancer research and public education.

Single-Dose Radiation Therapy for Breast Cancer Removes Treatment Barriers for Underserved Black Women

Retrieved on: 
Thursday, February 18, 2021
Medicine, Clinical medicine, Medical physics, Breast cancer, Radiation therapy, Treatment of cancer, External beam radiotherapy, Cancer, Intraoperative radiation therapy, Targeted intra-operative radiotherapy

The traditional approach to treating stage one or two breast cancer is tumor removal surgery followed by three to six weeks of daily External Beam Radiation Therapy (EBRT).

Key Points: 
  • The traditional approach to treating stage one or two breast cancer is tumor removal surgery followed by three to six weeks of daily External Beam Radiation Therapy (EBRT).
  • The arduous EBRT model is no longer necessary for many early-stage breast cancer cases.
  • However, within both of those income groups, Black women still experienced longer treatment durations than White women.
  • Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women, Cancer, September 21, 2020

Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients

Retrieved on: 
Monday, February 15, 2021
Research, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical trials, Science, Surgery, Biotechnology, FDA, Other Science, Health, Cancer, Treatment of cancer, Causes of death, Prostate cancer, Health, Gastrointestinal cancer, Infectious causes of cancer, Neoplasms, Professor Juan Marchal, Propanc Biopharma, Inc.

This is particularly significant, since the incidence of metastasis greatly reduces the life expectancy of cancer patients.

Key Points: 
  • This is particularly significant, since the incidence of metastasis greatly reduces the life expectancy of cancer patients.
  • Searching for new cancer treatments to achieve a definitive cure for cancer patients is my motivation.
  • I am very excited to see what our therapy can do for cancer patients in future clinical studies.
  • Prof Juan Antonio Marchal, M.D, Ph.D., is a Professor of Human Anatomy and Embryology (Faculty of Medicine) at the University of Granada.

Senti Bio to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, February 11, 2021
Branches of biology, Biology, Articles, Biotechnology, Immune system, Lymphocytes, Appropriate technology, Synthetic biology, Natural killer cell, Treatment of cancer

Senti Bio is a next-generation synthetic biology company that is developing gene circuits and programming cells for tremendous therapeutic value.

Key Points: 
  • Senti Bio is a next-generation synthetic biology company that is developing gene circuits and programming cells for tremendous therapeutic value.
  • By programming cells to respond, adapt and make decisions, Senti Bio is creating smarter therapies with computer-like logic, enhanced functionality and greater therapeutic control.
  • Senti Bio is developing a wholly-owned, gene circuit pipeline focused on allogeneic CAR-NK cells to address major challenges in cancer treatment.
  • Contact Senti Bio: Curt Herberts, CFO and CBO Email: [email protected] Denise Powell (Media) Email: [email protected]

Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference

Retrieved on: 
Thursday, February 11, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Branches of biology, MCRPC, Cancer, Clinical medicine, Prostate cancer, Glutamate carboxypeptidase II, Survival rate, Treatment of cancer, Sipuleucel-T, Prostvac

The results showed a median overall survival (mOS) of 19.7 months, exceeding all other mOS results for existing prostate cancer treatments in their own registration studies.

Key Points: 
  • The results showed a median overall survival (mOS) of 19.7 months, exceeding all other mOS results for existing prostate cancer treatments in their own registration studies.
  • This supports evidence that a combination of Veyonda (NOX66) and the experimental radiopharmaceutical, 177lutetium-PSMA-617, is a long-awaited leap forward in the treatment of metastatic castrate-resistant prostate cancer (mCRPC).
  • This offers a patient with mCRPC a high chance of the cancer responding to treatment to the extent of obtaining a meaningful survival outcome.
  • Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York.

Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children

Retrieved on: 
Wednesday, February 10, 2021
Biotechnology, Pharmaceutical, Oncology, Health, Children, Hospitals, Consumer, Clinical trials, Life sciences, Health sciences, Biopharmaceutical, Biotechnology, Pharmaceutical industry, Pharmacy, Treatment of cancer, Oncology, Cancer, Targeted therapy

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced a $130 million Series B financing from leading life sciences investors.

Key Points: 
  • Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced a $130 million Series B financing from leading life sciences investors.
  • Day One is a purpose-built company passionately committed to advancing important new cancer treatments for patients of all ages, with a focus on children.
  • With the completion of the Series B financing, Day One has raised more than $190 million from leading life science investors since the Company initiated operations in late 2019.
  • Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments.